ARTV vs. TERN, TSHA, ORKA, PHAT, ANNX, ATAI, CMRX, ESPR, ACB, and MBX
Should you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Terns Pharmaceuticals (TERN), Taysha Gene Therapies (TSHA), Oruka Therapeutics (ORKA), Phathom Pharmaceuticals (PHAT), Annexon (ANNX), Atai Life Sciences (ATAI), Chimerix (CMRX), Esperion Therapeutics (ESPR), Aurora Cannabis (ACB), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.
Artiva Biotherapeutics vs.
Terns Pharmaceuticals (NASDAQ:TERN) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.
98.3% of Terns Pharmaceuticals shares are owned by institutional investors. 15.1% of Terns Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Terns Pharmaceuticals received 33 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 60.87% of users gave Terns Pharmaceuticals an outperform vote.
Terns Pharmaceuticals currently has a consensus target price of $18.30, suggesting a potential upside of 356.36%. Artiva Biotherapeutics has a consensus target price of $21.00, suggesting a potential upside of 457.03%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Terns Pharmaceuticals.
Artiva Biotherapeutics' return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.
In the previous week, Artiva Biotherapeutics had 2 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 1 mentions for Terns Pharmaceuticals. Artiva Biotherapeutics' average media sentiment score of 0.45 beat Terns Pharmaceuticals' score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.
Summary
Artiva Biotherapeutics beats Terns Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
Get Artiva Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artiva Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARTV) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ARTV Stock Alerts